Suggested remit: To appraise the clinical and cost effectiveness of deucravacitinib within its marketing authorisation for treating moderate to severe plaque psoriasis.
Status Awaiting development
Process STA 2018
ID number 3859

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 07 December 2021 - 20 January 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
16 July 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-February 2022 when we will write to you about how you can get involved.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance